At the present time allergen immunotherapy (AIT) is the only causal intervention influencing the course of allergic disease. It is based on the application of increasing amounts of allergen to which the patient is oversensitive with the aim to reach the dose, which is effective in reaching diminution (disappearance) of symptoms caused by a contact with the causal allergen. The treatment is indicated in patients with allergic rhinitis, conjunctivitis and in allergy to insect bite. In previous time the immunotherapy with allergens was administered parenterally. In the last years increasing attention is paid to local (especially sublingual) route of administration. The authors describe their own experience in one-year sublingual AIT with Staloralon in 26 patients affected by manifestations of pollinosis. The monitoring of the disease manifestations during the pollen season revealed a significant decrease in the occurrence of ocular (P < 0.001), nasal (P < 0.001) and skin (P < 0.01) symptoms as well as symptoms of bronchial asthma (P < 0.01). Therewas a significant improvement of ocular (P < 0.04) and nasal (P < 0.03) symptoms between the second and third year of therapy, the improvement of symptoms of bronchial asthma and skin manifestations was not significant, possibly due to a lownumber of patients in the group. The results indicate amarked therapeutic effect of AIT in children with pollinosis, but the importance of this kind of therapy should be proved in a longer period of observation of the treated patients.

        Key words: allergen immunotherapy, indication and contraindication, pollinosis, children